Pfizer Still Looking To Buy A Tax Advantage – And Before Congress Flips
This article was originally published in Scrip
Pfizer Inc. CEO Ian Read said the company is evaluating tax inversion M&A opportunities but noted the big pharma would need to complete such a deal by the end of 2016, after which a new Congress would be in place – presenting further regulatory risks.
You may also be interested in...
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression.
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.